BlossomHill Therapeutics, Inc. (BLSM)
NASDAQ: BLSM · Real-Time Price · USD
13.94
-1.04 (-6.94%)
Oct 16, 2026, 4:00 PM EDT - Market closed
BlossomHill Therapeutics Stock Forecast
Stock Price Forecast
According to 5 analysts polled by S&P Global, BlossomHill Therapeutics stock has a consensus rating of "Strong Buy" and an average price target of $35.4. The average 1-year stock price forecast is 153.95% higher than the current stock price, while the lowest is $30 (+115.21%) and the highest is $40 (+186.94%).
Price Target: $35.4 (+153.95%)
Analyst Consensus: Strong Buy
Price Target
ChartAnalyst Ratings
The average analyst rating for BlossomHill Therapeutics stock is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| H.C. Wainwright | H.C. Wainwright | Buy Reiterates $35 | Buy | Reiterates | $35 | +151.08% | Sep 29, 2026 |
| J.P. Morgan | J.P. Morgan | Buy Maintains $30 | Buy | Maintains | $30 | +115.21% | Sep 24, 2026 |
| Leerink Partners | Leerink Partners | Buy Maintains $36 → $40 | Buy | Maintains | $36 → $40 | +186.94% | Sep 21, 2026 |
| Guggenheim | Guggenheim | Buy Maintains $30 → $40 | Buy | Maintains | $30 → $40 | +186.94% | Sep 18, 2026 |
| LifeSci Capital | LifeSci Capital | Buy Maintains $32 | Buy | Maintains | $32 | +129.56% | Sep 15, 2026 |
Financial Forecast
Revenue This Year
n/a
Revenue Next Year
n/a
EPS This Year
-5.10
EPS Next Year
-3.95
from -5.10
EPS and Forward PE are based on non-GAAP adjusted numbers.